目的 觀察胸腺肽聯(lián)合GP方案治療非小細(xì)胞肺癌的療效及對(duì)免疫功能和血管內(nèi)皮生長因子（VEGF）表達(dá)水平的影響。方法 選取2017年4月-2019年6月期間安康市中醫(yī)醫(yī)院收治的80名非小細(xì)胞肺癌患者作為研究對(duì)象，采用隨機(jī)數(shù)字表法分為對(duì)照組和觀察組，每組40例。對(duì)照組在第1天、第8天靜脈滴注注射用鹽酸吉西他濱，1.0 g/m²，1次/d，第1~3天靜脈滴注注射用順鉑，25 mg/m²，1次/d。觀察組在對(duì)照組的基礎(chǔ)上口服胸腺肽腸溶片，15 mg，2次/d。21 d為1個(gè)周期，兩組均治療2個(gè)周期。觀察兩組患者的近期臨床療效，比較兩組患者的KPS評(píng)分、免疫功能指標(biāo)和血管內(nèi)皮生長因子（VEGF）水平。結(jié)果 治療后，對(duì)照組客觀有效率（ORR）為47.50%，觀察組為57.50%，兩組差異無統(tǒng)計(jì)學(xué)差異。治療后，觀察組患者KPS評(píng)分優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者的CD4⁺、CD8⁺、CD4⁺/CD8⁺及NK細(xì)胞的比例與治療前有統(tǒng)計(jì)學(xué)差異（P<0.05）；治療后，觀察組患者CD4⁺、CD8⁺、CD4⁺/CD8⁺及NK細(xì)胞比例均優(yōu)于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)（P<0.05）。治療后，兩組VEGF水平均顯著降低（P<0.05）；與對(duì)照組相比，觀察組下降更為顯著（P<0.05）。結(jié)論 胸腺肽腸溶片聯(lián)合GP方案用于非小細(xì)胞肺癌的臨床治療，提高了患者的生存質(zhì)量和免疫功能，降低了血清VEGF水平。

Objective To observe the effect of thymopdypeptide combined with GP regimen on non-small cell lung cancer and its effect on immune function and expression level of VEGF. Methods A total of 80 patients with non small cell lung cancer in the Ankang Hospital of Traditional Chinese Medicine from April 2017 to June 2019 were selected as research objects, and randomly divided into the control group and the observation group, with 40 cases in each group. Patients in the control group were iv administerted with Gemcitabine Hydrochloride Injection for D1 and D8, 1.0 g/m², once daily, and iv administerted with Cisplatin for Injection from D1 to D3, 25 mg/m², once daily. Patients in observation group were po administered with Thymopdypeptide EntericCoated Tablets on the basis of control group, 15 mg, twice daily. 21 d was 1 cycle, and both groups were treated for 2 cycles. The short-term clinical efficacy in two groups was observed, and the KPS score, immune function index, and VEGF in two groups were compared. Results After treatment, the objective effective rate (ORR) was 47.50% in the control group, and 57.50% in the observation group, there was no statistical difference between the two groups. After treatment, the KPS score in the observation group was better than that in the control group, and the difference between the two groups was statistically significant (P<0.05). After treatment, the proportions of CD4⁺, CD8⁺, CD4⁺/CD8⁺, and NK cells in two groups were statistically different from those before treatment (P<0.05). After treatment, the proportions of CD4⁺, CD8⁺, CD4⁺/CD8⁺ and NK cells in the observation group were better than those in the control group, with statistically significant differences (P<0.05). After treatment, VEGF levels in two groups were significantly reduced (P<0.05). Compared with the control group, the decrease was more significant in the observation group (P<0.05). Conclusion Thymopdypeptide Enteric-Coated Tablets combined with GP regimen in treatment of non-small cell lung cancer, can improved the quality of life and immune function of patients, and reduced the serum VEGF level.

R979.1

陜西省科技惠民計(jì)劃項(xiàng)目（2016HM-09）